Genmab A (GMAB) Receivables - Other (2023 - 2025)
Genmab A's Receivables - Other history spans 3 years, with the latest figure at $62.0 million for Q4 2025.
- For Q4 2025, Receivables - Other rose 26.53% year-over-year to $62.0 million; the TTM value through Dec 2025 reached $62.0 million, up 26.53%, while the annual FY2025 figure was $62.0 million, 26.53% up from the prior year.
- Receivables - Other reached $62.0 million in Q4 2025 per GMAB's latest filing, up from $49.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $62.0 million in Q4 2025 to a low of $43.0 million in Q4 2023.
- Average Receivables - Other over 3 years is $51.3 million, with a median of $49.0 million recorded in 2024.
- Peak YoY movement for Receivables - Other: increased 13.95% in 2024, then increased 26.53% in 2025.
- A 3-year view of Receivables - Other shows it stood at $43.0 million in 2023, then rose by 13.95% to $49.0 million in 2024, then grew by 26.53% to $62.0 million in 2025.
- Per Business Quant, the three most recent readings for GMAB's Receivables - Other are $62.0 million (Q4 2025), $49.0 million (Q4 2024), and $43.0 million (Q4 2023).